Looks like you’re on the UK site. Choose another location to see content specific to your location
FDA Greenlights BioIntelliSense’s BioButton Copy
BioIntelliSense, a leader in health monitoring technology, has secured U.S. FDA approval for its BioButton Multi-Patient wearable and BioDashboard system. This innovative solution enables continuous monitoring of vital signs, promising to transform how patient care is delivered both in hospitals and at home.
The BioButton and BioDashboard system offer a platform for automating the collection of vital signs across diverse healthcare settings. These technologies provide a significant shift from traditional episodic monitoring to continuous observation, allowing early detection of physical changes and intervention to improve patient outcomes.
The system’s data-driven approach provide healthcare systems with the opportunity to manage numerous patients concurrently, optimizing clinical workflows and enhancing resource allocation. BioIntelliSense’s comprehensive platform, which includes these wearables, BioHub Wi-Fi gateways, and BioCloud data analytics, is designed to streamline manual processes and facilitate proactive clinical decision-making.
With the introduction of the rechargeable and reusable BioButton, BioIntelliSense is setting a new standard in patient monitoring that extends from hospital to home care. This FDA approval marks a significant milestone for the company, enabling broader access to continuous care solutions. The integration of these advanced devices is set to improve patient safety, enhance clinical efficiency, and make continuous monitoring more affordable and accessible, paving the way for a more innovative healthcare future.
For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough technology, industry trends, and regulatory news, contact Mark Atkinson today!
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard